A new review maps how mavacamten and aficamten are reshaping the treatment pathway for hypertrophic obstructive ...
A new review in Cardiovascular Ultrasound synthesizes how advanced imaging, genetic testing and cardiac myosin inhibitors are ...
Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, ...
Muscle isn’t the only place where nature has solved the problem of coordinating many tiny motors. Microscopic flagella are ...
Aficamten, a cardiac myosin inhibitor, was associated with improvements in symptom relief, diastolic function and parameters ...
There aren't that many cardiology companies on the NASDAQ but Cytokinetics (NDQ:CYTK) is one of them. And it is no ordinary ...
When you open a gyoza recipe, there is a standard set of instructions you will almost certainly encounter.Add salt to the ...
Dietary fiber and microbial metabolites influence intestinal barrier function and immune responses, with animal studies ...
Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, ...
Josie Zayner infamously injected herself with CRISPR on a livestream. Now her company is gene-editing horse, cat and cattle embryos as a first step towards more mythical creatures ...
If a young person has syncope and a family history, strongly suspect structural heart disease.---â– First, just these 3 ...
The 2025 Congestive Heart Failure market size was approximately USD 9,000 million and is projected to reach approximately USD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results